Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Leukemia. 2010 Nov 12;25(2):305–312. doi: 10.1038/leu.2010.257

Figure 3. Effect of Grb2 shRNAs on normal and BCR-ABL-transformed CD34+ progenitor cell growth.

Figure 3

(A) BCR-ABL-transformed or (B) control CB CD34+ cells expressing the indicated shRNAs were cultured with low concentrations of GF and the number of viable cells counted on day 7 and 14. Viable cells per 100,000 input CD34+GFP+RFP+ cells are shown. Significance levels: * p < 0.03, n=8; ** p < 0.002, n=2, compared to controls. (C) BCR-ABL-transformed or control CD34+ cells expressing the indicated shRNAs were cultured with low GF concentrations for five days and cell proliferation determined using an MTS assay. Results are from three independent experiments each done in triplicate. Significance levels: *, P < 0.03, MIG210+ctr shRNA versus MIG210+Grb2-2 shRNA. (D) BCR-ABL-transformed cells expressing the indicated shRNAs were cultured in high GF conditions for seven days, n = 3.